DNMT3A and myelodysplastic syndrome: Hydralazine has also been reported to suppress DNMT3a expression [20–22], and DNMT3A mutations are implicated in the development of various hematologic neoplasms [23], including myeloproliferative neoplasms, MDS [24], acute myeloid leukemia (AML) [25–27], and T-cell lymphoma [28].